three months ended June 30, 2026
Filed Aug 4, 2026Odyssey Therapeutics furnished an 8-K announcing financial results for the three months ended June 30, 2026, but the supplied filing text does not include Exhibit 99.1 or any underlying earnings release financial data.
The filing confirms an earnings announcement but provides no reported operating, financial, liquidity, capital-return, or guidance figures in the supplied text.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|
Concerns
- Exhibit 99.1, identified as the press release dated August 4, 2026, is not included in the supplied filing text.
- No revenue, expense, earnings, cash-flow, liquidity, balance-sheet, clinical-program, or guidance disclosure is available in the supplied text.
What to watch
- The contents of Exhibit 99.1, including financial statements, cash runway commentary, operating expenses, and any development-program updates.
- Any forward-looking financial or clinical guidance contained in the omitted earnings press release.
Analysis
Odyssey Therapeutics furnished its Form 8-K under Item 2.02 on August 4, 2026 and stated that it announced financial results for the three months ended June 30, 2026. The supplied text identifies Exhibit 99.1 as the related press release dated August 4, 2026, but does not provide that exhibit or reproduce its contents.
As a result, the supplied document contains no reported revenue, research and development expense, general and administrative expense, operating loss, net loss, earnings per share, or non-GAAP measures. There is also no segment disclosure, so demand trends, revenue mix, margins, and changes from the prior year or prior quarter cannot be assessed from this filing text.
The filing does not disclose operating cash flow, free cash flow, cash and equivalents, debt, share repurchases, dividends, or other capital-allocation information. Accordingly, the company's liquidity position and spending profile cannot be evaluated using the available document.
No outlook or guidance is included in the supplied text, and no prior outlook was provided for comparison. The central item for investors is the omitted Exhibit 99.1, which is the only referenced source for the quarter's financial results and any management commentary.
Not in the filing
stated, not guessed- Exhibit 99.1 earnings press release
- Total revenue
- Revenue comparisons and growth rates
- Segment revenue, comparisons, and drivers
- Gross profit and gross margin
- Research and development expense
- General and administrative expense
- Operating expenses
- Operating income or loss
- Net income or loss
- GAAP earnings or loss per share
- Non-GAAP earnings measures
- Operating cash flow
- Free cash flow
- Cash and cash equivalents
- Debt
- Share repurchases
- Dividends
- Forward guidance
- Prior-period guidance for comparison
- Management commentary and named-executive quotes
- Clinical, product, or commercial operating updates
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.